Article

HIMSS Praises Health IT in GOP's Platform

One healthcare interest group expressed support for a portion of the Republican Party's platform and said it could be an area of common ground with Democrats.

Released Tuesday, the GOP's official platform supports "technology enhancements for medical health records and data systems while affirming patient privacy and ownership of health information."

Read the full story:

http://bit.ly/SWtflj

Source: ModernHealthcare.com

Related Videos
Mei Wei, MD.
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Sandra Cueller, PharmD
Ticiana Leal, MD
James Chambers, PhD
Related Content
Boy with DMD using walker | Image credit: Svitlana – stock.adobe.com
November 23rd 2024

Viltolarsen Slows DMD Progression in Small Study

Hayden E. Klein
Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).
Managed Care Cast
November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi
The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.
Tooth loss | Image Credit: © valiantsin-stock.adobe.com
November 23rd 2024

Edentulism May Heighten Sleep Apnea Risk

Jared Kaltwasser
A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Center on Health Equity and Access
November 23rd 2024

Health Equity & Access Weekly Roundup: November 23, 2024

Giuliana Grossi
Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
FDA website | Image Credit: © Postmodern Studio - stock.adobe.com
November 22nd 2024

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Marco Meglio
The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo